Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VRDN
Upturn stock ratingUpturn stock rating

Viridian Therapeutics Inc (VRDN)

Upturn stock ratingUpturn stock rating
$18.44
Last Close (24-hour delay)
Profit since last BUY30.32%
upturn advisory
Consider higher Upturn Star rating
BUY since 50 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VRDN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

16 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $37.94

1 Year Target Price $37.94

Analysts Price Target For last 52 week
$37.94 Target price
52w Low $9.9
Current$18.44
52w High $27.2

Analysis of Past Performance

Type Stock
Historic Profit 22.95%
Avg. Invested days 33
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.51B USD
Price to earnings Ratio -
1Y Target Price 37.94
Price to earnings Ratio -
1Y Target Price 37.94
Volume (30-day avg) 16
Beta 0.48
52 Weeks Range 9.90 - 27.20
Updated Date 08/15/2025
52 Weeks Range 9.90 - 27.20
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.57

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When -
Estimate -1
Actual -1

Profitability

Profit Margin -
Operating Margin (TTM) -142356%

Management Effectiveness

Return on Assets (TTM) -39.77%
Return on Equity (TTM) -65.88%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1152724084
Price to Sales(TTM) 4937.23
Enterprise Value 1152724084
Price to Sales(TTM) 4937.23
Enterprise Value to Revenue 3779.42
Enterprise Value to EBITDA -3.18
Shares Outstanding 81662400
Shares Floating 67246511
Shares Outstanding 81662400
Shares Floating 67246511
Percent Insiders 0.16
Percent Institutions 115.64

ai summary icon Upturn AI SWOT

Viridian Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Viridian Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel therapies for patients suffering from serious diseases but currently no available approved products to sell. Founded in 2017, Viridian has focused on the development of treatments for thyroid eye disease (TED).

business area logo Core Business Areas

  • Thyroid Eye Disease (TED) Therapeutics: Viridian focuses on developing novel antibody therapies for TED, an autoimmune disease causing inflammation and damage to tissues around the eyes.

leadership logo Leadership and Structure

Scott Myers is the CEO. The company has a board of directors and operates with a typical biotechnology organizational structure, emphasizing research and development.

Top Products and Market Share

overview logo Key Offerings

  • VRDN-001: VRDN-001 is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). It is being developed for the treatment of Thyroid Eye Disease. VRDN-001 is currently in Phase 3 clinical trials. Competitors include Tepezza (teprotumumab-trbw) by Horizon Therapeutics, a now Amgen company. Market share information for VRDN-001 is unavailable as it is not yet approved.
  • VRDN-003: VRDN-003 is a new molecule under development. VRDN-003, an anti-IGF-1R antibody product candidate, is designed to potentially offer better convenience, tolerability, and efficacy than current therapies. Competitors are similar to VRDN-001, including Tepezza. Market share information is not available as VRDN-003 is not yet approved.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and research-intensive, focused on developing new therapeutics. The market for TED therapeutics is growing, driven by increased diagnosis rates and unmet medical needs.

Positioning

Viridian is positioned as an innovator in the TED therapeutic space, aiming to improve upon existing treatments with potentially more effective and convenient therapies.

Total Addressable Market (TAM)

The global TED market is projected to reach multi-billion dollars in the coming years. Viridian's success depends on the successful development and approval of their product candidates and being competive. Viridian aims to capture a significant portion of this market.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic candidates targeting IGF-1R for TED
  • Experienced management team
  • Strong intellectual property portfolio

Weaknesses

  • Reliance on successful clinical trial outcomes
  • No currently marketed products, resulting in no revenue stream
  • High cash burn rate typical of development-stage biotech companies

Opportunities

  • Potential to capture significant market share in the TED market
  • Expansion into other autoimmune diseases
  • Partnerships or acquisitions by larger pharmaceutical companies

Threats

  • Clinical trial failures
  • Competition from established players like Horizon Therapeutics(Amgen)
  • Regulatory hurdles and delays

Competitors and Market Share

competitor logo Key Competitors

  • AMGN

Competitive Landscape

Viridian's advantage lies in developing potentially improved anti-IGF-1R antibodies. The primary disadvantage is that they don't have any approved products and compete against established players, now Amgen, with approved and marketed products.

Growth Trajectory and Initiatives

Historical Growth: Since its founding, Viridian's growth has been characterized by advancing its pipeline of therapeutic candidates through preclinical and clinical development stages.

Future Projections: Future growth is contingent upon the successful completion of clinical trials and regulatory approval of its product candidates. Analyst estimates vary, but positive trial outcomes could lead to significant stock appreciation.

Recent Initiatives: Recent initiatives include advancing VRDN-001 and VRDN-003 through clinical trials, presenting clinical data at scientific conferences, and securing financing to support ongoing R&D activities.

Summary

Viridian Therapeutics is a development-stage biotechnology company with promising therapeutic candidates for TED. The company is focusing its efforts on advancing VRDN-001 and VRDN-003 through clinical trials. A risk is if it doesn't get approved or it is outperformed by its competitors. Viridian's success depends on the positive clinical trial outcomes and market acceptance of its products.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Viridian Therapeutics Inc

Exchange NASDAQ
Headquaters Waltham, MA, United States
IPO Launch date 2014-06-18
CEO, President & Director Mr. Stephen F. Mahoney J.D., MBA
Sector Healthcare
Industry Biotechnology
Full time employees 143
Full time employees 143

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.